NICE tackles "major challenge" of radical colorectal cancer therapy costs
This article was originally published in Clinica
The early diagnosis of suspicious symptoms, variations in care policy and the "major economics challenge" posed by radical therapies are among the issues that the UK's National Institute for Health and Clinical Excellence (NICE) will focus on to develop a clinical practice guideline for colorectal cancer. Its proposed scope is now out for consultation, until March 18.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.